nitrocefin and Tuberculosis

nitrocefin has been researched along with Tuberculosis* in 1 studies

Other Studies

1 other study(ies) available for nitrocefin and Tuberculosis

ArticleYear
Evaluation of biochemical and molecular polymorphism in extended spectrum β-lactamases of Mycobacterium tuberculosis clinical isolates.
    The Indian journal of tuberculosis, 2019, Volume: 66, Issue:1

    Tuberculosis (TB) caused 1.8 million deaths worldwide with increased multiple drug resistance (MDR) cases estimated 4.8 lakhs in the year 2015. β-Lactam antibiotics could be a hope for TB treatment. Therefore, in this study, uniformity in the biochemical and molecular nature of β-lactamases was analyzed to evaluate the potential of β-lactam antibiotics as a treatment regimen against Mycobacterium tuberculosis (MTB).. β-Lactamase enzymes in 233 MTB clinical isolates along with control H37Rv strain were characterized by enzyme kinetic using nitrocefin and cefotaxime as a substrate, isoelectric points by isoelectric focusing electrophoresis (IEF) and by PCR and Southern blotting.. This confirmed that MTB β-lactamase enzymes belong to the Class A, group 2be Extended Spectrum β-Lactamases with no biochemical or molecular polymorphism. ESBLs are mainly responsible for resistance against β-lactam antibiotics in MTB. Thus ESBLs could be the potential therapeutic target for TB treatment using β-lactam antibiotics in combination with β-lactamase inhibitors like sulbactam and sodium clavulanate.

    Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Blotting, Southern; Cefotaxime; Cephalosporins; Clavulanic Acid; Humans; Isoelectric Focusing; Kinetics; Mycobacterium tuberculosis; Polymerase Chain Reaction; Tuberculosis

2019